Marshall Wace LLP Reduces Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Marshall Wace LLP cut its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 43.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 951,432 shares of the company's stock after selling 719,301 shares during the period. Marshall Wace LLP owned about 1.80% of Stoke Therapeutics worth $10,494,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in STOK. Renaissance Technologies LLC bought a new position in Stoke Therapeutics during the 4th quarter worth about $1,423,000. Invesco Ltd. bought a new position in shares of Stoke Therapeutics during the fourth quarter worth about $133,000. Wells Fargo & Company MN lifted its stake in Stoke Therapeutics by 51.2% in the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock valued at $185,000 after acquiring an additional 5,682 shares in the last quarter. Geode Capital Management LLC boosted its position in Stoke Therapeutics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 877,095 shares of the company's stock worth $9,677,000 after acquiring an additional 6,264 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $3,472,000.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average target price of $24.67.

Stoke Therapeutics Trading Down 1.2 %

NASDAQ STOK traded down $0.12 during midday trading on Friday, hitting $9.76. The company had a trading volume of 582,252 shares, compared to its average volume of 714,358. The firm has a 50-day moving average price of $7.79 and a 200-day moving average price of $10.31. The company has a market capitalization of $527.80 million, a PE ratio of -4.65 and a beta of 1.09. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 over the last quarter. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.